HIKAL
|
HIKAL Last 5 Year Financial Ratios History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 6.36 | 13.02 | 10.80 | 6.85 | 8.36 |
CEPS(Rs) | 15.20 | 20.78 | 17.71 | 13.54 | 15.89 |
DPS(Rs) | 1.20 | 1.60 | 2.00 | 1.20 | 1.20 |
Book NAV/Share(Rs) | 91.93 | 86.62 | 75.70 | 66.22 | 61.33 |
Tax Rate(%) | 25.61 | 26.56 | 35.50 | 33.29 | 30.86 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 12.71 | 17.53 | 18.77 | 18.12 | 18.75 |
EBIT Margin(%) | 7.59 | 12.86 | 14.10 | 11.88 | 13.05 |
Pre Tax Margin(%) | 5.21 | 11.25 | 12.00 | 8.40 | 9.38 |
PAT Margin (%) | 3.87 | 8.26 | 7.74 | 5.60 | 6.48 |
Cash Profit Margin (%) | 9.26 | 13.19 | 12.69 | 11.07 | 12.33 |
Performance Ratios | |||||
ROA(%) | 3.27 | 7.39 | 6.84 | 4.62 | 6.11 |
ROE(%) | 7.12 | 16.04 | 15.22 | 10.74 | 14.46 |
ROCE(%) | 8.47 | 15.21 | 16.15 | 12.44 | 15.25 |
Asset Turnover(x) | 0.84 | 0.89 | 0.88 | 0.82 | 0.94 |
Sales/Fixed Asset(x) | 1.37 | 1.54 | 1.57 | 1.49 | 1.82 |
Working Capital/Sales(x) | 7.29 | 9.96 | 7.76 | 8.45 | 6.99 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.73 | 0.65 | 0.64 | 0.67 | 0.55 |
Receivable days | 79.34 | 86.73 | 87.62 | 83.56 | 73.14 |
Inventory Days | 58.25 | 55.96 | 61.44 | 81.93 | 76.61 |
Payable days | 92.70 | 87.68 | 86.55 | 84.90 | 69.37 |
Valuation Parameters | |||||
PER(x) | 44.34 | 30.92 | 13.29 | 10.22 | 20.93 |
PCE(x) | 18.55 | 19.37 | 8.10 | 5.17 | 11.01 |
Price/Book(x) | 3.07 | 4.65 | 1.90 | 1.06 | 2.85 |
Yield(%) | 0.43 | 0.40 | 1.39 | 1.71 | 0.69 |
EV/Net Sales(x) | 2.06 | 2.88 | 1.36 | 0.96 | 1.75 |
EV/Core EBITDA(x) | 15.87 | 16.17 | 7.14 | 5.22 | 9.28 |
EV/EBIT(x) | 27.13 | 22.37 | 9.65 | 8.07 | 13.43 |
EV/CE(x) | 1.69 | 2.40 | 1.16 | 0.77 | 1.57 |
M Cap / Sales | 1.72 | 2.55 | 1.03 | 0.57 | 1.36 |
Growth Ratio | |||||
Net Sales Growth(%) | 4.13 | 12.92 | 14.14 | -5.18 | 22.65 |
Core EBITDA Growth(%) | -24.02 | 5.36 | 18.42 | -7.83 | 22.01 |
EBIT Growth(%) | -38.56 | 2.95 | 35.55 | -13.74 | 29.20 |
PAT Growth(%) | -51.16 | 20.55 | 57.68 | -18.08 | 33.47 |
EPS Growth(%) | -51.16 | 20.55 | 57.68 | -18.08 | -11.02 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.66 | 0.63 | 0.65 | 0.79 | 0.87 |
Current Ratio(x) | 1.40 | 1.24 | 1.32 | 1.27 | 1.35 |
Quick Ratio(x) | 0.94 | 0.84 | 0.94 | 0.79 | 0.79 |
Interest Cover(x) | 3.19 | 8.00 | 6.70 | 3.41 | 3.55 |
Total Debt/Mcap(x) | 0.22 | 0.14 | 0.34 | 0.75 | 0.31 |
Compare Financial Ratios of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹3,850.7 Cr | -2.4% | 12.7% | 5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | -2.4% |
12.7% |
5% |
SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses